Viridian Therapeutics, Inc.

VRDN · NASDAQ
Analyze with AI
9/30/2025
6/30/2025
3/31/2025
12/31/2024
Operating Activities
Net Income-$35-$101-$87-$80
Dep. & Amort.$0$0$0$0
Deferred Tax$0$0$0$0
Stock-Based Comp.$11$11$10$9
Change in WC-$60$16-$14$0
Other Non-Cash-$1-$1-$2-$3
Operating Cash Flow-$85-$75-$93-$73
Investing Activities
PP&E Inv.-$0-$0-$0-$0
Net Acquisitions$0$0$0$0
Inv. Purchases-$14-$56-$71-$182
Inv. Sales/Matur.$140$132$171$119
Other Inv. Act.$0$0$0$0
Investing Cash Flow$126$76$100-$63
Financing Activities
Debt Repay.$0$0$0$0
Stock Issued$10$0$5$34
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.$1$1$4$2
Financing Cash Flow$11$1$9$36
Forex Effect$0$0$0$0
Net Chg. in Cash$52$1$17-$101
Supplemental Information
Beg. Cash$117$116$100$200
End Cash$170$117$116$100
Free Cash Flow-$85-$75-$93-$73
Viridian Therapeutics, Inc. (VRDN) Financial Statements & Key Stats | AlphaPilot